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Fibromyalgia is characterized by chronic pain and a striking discrepancy between objective
signs of tissue damage and severity of pain. Function and structural alterations in brain
areas involved in pain processing may explain this feature. Previous case-control studies in
fibromyalgia focused on acute pain processing using experimentally-evoked pain para-
digms. Yet, these studies do not allow conclusions about chronic, stimulus-independent
pain. Resting-state cerebral blood flow (rsCBF) acquired by arterial spin labelling (ASL) may
be a more accurate marker for chronic pain. The objective was to integrate four different
functional and structural neuroimaging markers to evaluate the neural correlate of chronic,
stimulus-independent pain using a resting-state paradigm. In line with the pathophysiologi-
cal concept of enhanced central pain processing we hypothesized that rsCBF is increased
in fibromyalgia in areas involved in processing of acute pain. We performed an age matched
case-control study of 32 female fibromyalgia patients and 32 pain-free controls and calcu-
lated group differences in rsCBF, resting state functional connectivity, grey matter volume
and cortical thickness using whole-brain and region of interest analyses. We adjusted all
analyses for depression and anxiety. As centrally acting drugs are likely to interfere with
neuroimaging markers, we performed a subgroup analysis limited to patients not taking
such drugs. We found no differences between cases and controls in rsCBF of the thalamus,
the basal ganglia, the insula, the somatosensory cortex, the prefrontal cortex, the anterior
cingulum and supplementary motor area as brain areas previously identified to be involved
in acute processing in fibromyalgia. The results remained robust across all neuroimaging
markers and when limiting the study population to patients not taking centrally acting drugs
PLOS ONE
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and matched controls. In conclusion, we found no evidence for functional or structural alter-
ations in brain areas involved in acute pain processing in fibromyalgia that could reflect neu-
ral correlates of chronic stimulus-independent pain.
Introduction
Fibromyalgia is characterized by chronic and widespread pain with additional symptoms such
as fatigue, sleep disturbance and cognitive dysfunctions [1–3]. The Impact on quality of life is
comparable to other chronic diseases such as rheumatoid arthritis, diabetes mellitus and
chronic obstructive lung disease [4, 5]. Therapeutic options remain limited with modest effects
for most treatments and a high proportion of patients not responding to any treatment [6].
Despite the clinical significance of the disease, pathophysiological processes remain poorly
understood which limits the development of diagnostic markers and novel treatments target-
ing pathophysiological mechanisms rather than disease symptoms.
The striking discrepancy between objective signs of tissue damage and magnitude of pain
suggests a pathophysiological process involving the central nervous system with possible alter-
ations in brain function and structure [7, 8]. A state of enhanced central pain response associ-
ated with increased neural activity in pain processing brain areas may lead to exaggerated pain
response even to non-painful stimuli, high stimulus-independent pain and widespread pain
[7, 9–14]. Brain areas identified to be involved in pain processing include subcortical regions
such as thalamus and basal ganglia and the insula, somatosensory cortex, prefrontal cortex,
anterior cingulum and supplementary motor area as cortical regions [8, 15, 16]. It remains
however a subject of debate whether these brain areas are mainly processing acute pain signals
or whether they also involved in chronic pain [8, 17]. Potential neuroimaging markers of
chronic pain include resting-state cerebral blood flow (rsCBF) or functional connectivity on a
functional level, as well as alterations of grey matter volume and cortical thickness on a struc-
tural level.
First neuroimaging studies investigating functional markers mainly focused on the compar-
ison of acute pain processing mechanisms in fibromyalgia patients and pain-free controls
using experimentally-evoked pain paradigms and blood oxygenation level dependent (BOLD)
contrasts [7, 8]. In line with the pathophysiological concept of enhanced central pain response,
these studies detected increased neural activity in the amygdala, the insula, the somatosensory
cortex and the cingulate cortex of fibromyalgia patients after painful stimuli. However, for two
reasons, these studies do not allow conclusions about processing of chronic, stimulus-indepen-
dent pain that typically remains constant over time [18–20]. First, the studies used experimen-
tally evoked acute pain paradigms rather than resting-state paradigms that are more likely to
capture neural adaptation to chronic pain. Second, even if the researchers acquired resting-
state data, they used BOLD contrasts and quantified resting-state connectivity as marker of
chronic pain [21, 22] rather than specific regional resting-state neural activity. However, while
BOLD provides a relative and indirect measure of brain activity, rCBF gives an absolute value
that is directly related to local brain metabolism and thus appears perfectly suited to quantify
neural activity in chronic pain.
Arterial spin labelling (ASL) as an advanced neuroimaging method quantifies resting-state
cerebral flow (rsCBF) as a direct marker of neural activity at rest [17, 23]. First studies using
ASL in different chronic pain conditions such as chronic low back pain [24, 25], postsurgical
pain [26], trigeminal neuropathy [27], postherpetic neuralgia [28] and fibromyalgia [29] are
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emerging. Although these studies employed a resting-state paradigm, they only partly
accounted for important confounders such as depression, age, and gender, while they failed to
consider centrally acting drugs potentially biasing neuroimaging markers. This may explain
why the results of the studies remain inconclusive. Additionally, previous studies did not
integrate functional and structural neuroimaging by applying multimodal neuroimaging.
We conducted a multimodal neuroimaging study integrating functional and structural
markers to explore the neural correlates of chronic pain in fibromyalgia. The primary objective
was to compare rsCBF patterns of fibromyalgia patients and pain-free controls using ASL. In
line with the paradigm of enhanced central pain response we hypothesized that rsCBF in areas
involved in pain processing is increased in fibromyalgia. The secondary objective was to com-
pare resting-state functional connectivity between pre-specified Regions of Interest, grey mat-
ter volume and cortical thickness between cases and controls assuming a reduction in these
neuroimaging markers in fibromyalgia. We adjusted all our analyses for depression and anxi-
ety and conducted a subgroup analysis limited to patients free of any centrally acting drugs.
Material and methods
Participants and study design
We performed a 1:1 frequency age-matched case-control study in fibromyalgia patients and
pain-free controls using 10 years age bands. We centrally recruited right-handed [30] female
participants at the University Hospital of Bern, Switzerland. We randomly sampled cases from
a pool of 238 patients who were first diagnosed with fibromyalgia at either the Department
of Rheumatology, the Department of Psychosomatic Medicine or the Pain Clinic between
November 2013 and January 2015. We randomly sampled controls from a pool of 9253
women who presented during the same period at the Emergency Department. We stopped
sampling when we reached the required sample size. We included controls if they did not suf-
fer from any chronic pain disorder and were pain-free two weeks prior to neuroimaging. We
included cases if they were confirmed with the diagnosis of fibromyalgia according to the diag-
nostic criteria of the American College of Rheumatology at repeat clinical examination at
enrollment [2]. Their diagnostic criteria are based on the Widespread Pain Index, which char-
acterizes spread of pain, and the Symptom Severity Scale, which assesses different core symp-
toms of fibromyalgia including depression that is frequently encountered in these patients. We
therefore did not exclude patients with co-morbid depression from the study but adjusted our
analyses for severity of depression measured by the Beck-Depression Inventory version 2 [31]
as described in the statistical section.
Common exclusion criteria for cases and controls were conditions interfering with the MRI
acquisition; neurologic co-morbidity or history of neurosurgical intervention; psychiatric co-
morbidity other than unipolar depressive disorder; end-stage somatic co-morbidity defined as
untreatable disease that represents a threaten for life in the next few months; intake of strong
opioids or any psychopharmacological treatment other than anticonvulsants or antidepres-
sants; inability to understand the consequences of study participation; and pregnancy. We per-
formed the study according to a prospective protocol approved by the ethics committee of the
Canton Bern, Switzerland (KEK 43/13), and in accordance with the Declaration of Helsinki
[32]. All participants gave written informed consent.
Assessment of socio-demographic, psychological and clinical characteristics
We assessed the following socio-demographic and psychological characteristics in all partici-
pants: age; education (higher education vs lower education); marital status (married vs not
married); depression and anxiety. We considered participants with high school or university
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degree as having higher education. We used the Beck Depression Inventory version 2 (BDI-II)
[31] and the State-Trait-Anxiety-Inventory (STAI) [33] to assess depression and anxiety in all
participants. In cases we additionally assessed pain intensity, pain duration, spread of pain and
disability. We used the Numerical Rating Scale to measure average pain intensity within the
last 24 hours, pain intensity immediately before neuroimaging (NRS, 0 = no pain to 10 = worst
pain) and the Fibromyalgia Impact Questionnaire to assess disability (FIQ, 0 = no disability,
100 = most severe disability) [34]. We used the Widespread Pain Index to characterize the
spread of pain with (WPI, 0 = no body region with pain to 19 = generalized pain affecting all
body regions) [2]. We recorded long-term daily intake of centrally acting drugs such as light
opioids, antidepressants or anticonvulsants. The patients took these drugs also on the day of
neuroimaging.
Neuroimaging
Image acquisition. We performed multimodal neuroimaging at the Institute of Neurora-
diology of the University Hospital of Bern to acquire four neuroimaging markers: resting-state
cerebral blood flow (rsCBF); resting-state functional connectivity (rsFC); grey matter volume
(GMV); and cortical thickness (CoTh). We performed the MRI with a 3-Tesla Trio whole-
body scanner using a 12-channel radio-frequency head coil (Siemens Medical, Germany). All
study participants were instructed to lie quietly with eyes closed not thinking of anything par-
ticular during functional scans. We obtained the sequences in the following order:
First, high resolution anatomical T1� weighted images: 176 sagittal slices with 256 × 224
matrix points with a non-cubic field of view (FOV) of 256 mm × 224 mm, yielding a nominal
isotropic resolution of 1 mm3 (i.e. 1mm × 1mm × 1mm), repetition time (TR) = 7.92ms, echo
time (TE) = 2.48ms, flip angle = 16˚, inversion with symmetric timing (inversion time 910ms).
Second, a set of 80 functional T2� weighted images using a pseudo-continuous arterial spin
labelling sequence (pCASL) which corresponds to 40 pairs of unlabeled and labeled images
[35, 36]: eighteen axial slices at a distance of 1.0 mm; slice thickness = 6.0 mm; FOV =
230 x 230 mm2; matrix size = 128 x 128, yielding a voxel-size of 1.8mm × 1.8mm × 6mm;
TR = 4000ms; TE = 18ms. The gap between the labeling slab and the proximal slice was 90
mm; gradient-echo; echo-planar readout; ascending order; acquisition time 45 ms per slice.
Slice-selective gradient 6 mT/m, post-labeling delay w = 1250 ms, tagging duration τ = 1600
ms.
Third, BOLD functional T2� weighted images were acquired with an echo planar imaging
(EPI) sequence: 32 axial slices, FOV = 192x192 mm2, matrix size = 64x64, gap thickness = 0.75
mm, resulting in a voxel size of 3x3x3 mm3, TR/TE 1980ms/30ms, flip angle = 90˚, band-
width = 2232Hz/Px, echo spacing = 0.51ms, 460 volumes.
Selection of Region of Interests (ROIs). Even though our main statistical approach was
to perform voxel- and vertex-wise whole-brain analyses, we also investigated several pre-speci-
fied cortical Regions of Interests (ROIs) likely to be involved in pain processing in fibromyalgia
based on previous evidence for functional neuroimaging markers [8] and on atlases for struc-
tural markers [37, 38]. We did not investigate software specific ROIs. For functional analyses
of rsCBF and rsFC we defined the exact coordinates of 11 ROIs according to a recent meta-
analysis by Dehghan et al [8]: Bilateral insula, left anterior and middle cingulate cortex (ACC,
MCC), right Amygdala, bilateral superior temporal gyrus (STG), right lingual gyrus and left
primary and secondary cortex (S I, S II). Notably, the right insula is represented in two ROIs
in this selection while all other brain regions are represented by one ROI each. We created a
box around the coordinates with size = 27 voxels (216 mm3). For structural analyses of GMV
and CoTh we selected brain regions that represent the above specified regions from existing
PLOS ONE Neuroimaging central pain processing fibromyalgia
PLOS ONE | https://doi.org/10.1371/journal.pone.0235879 February 2, 2021 4 / 18
atlases. This resulted in 10 volumetric ROIs based on the Automatic Anatomical Labeling
(AAL)-Atlas for GMV analyses [37] and 23 ROIs based on the Destrieux-Atlas which is based
on gyral and sulcal surface for CoTh analyses [38]. We extracted rsCBF and grey matter values
in for ROIs using MarsBaR (Version 0.44, http://marsbar.sourceforge.net/).
Image preprocessing and calculation of functional and structural neuroimaging mark-
ers. We performed structural preprocessing for rsCBF, and GMV analyses in SPM12 (Revi-
sion 6225, Welcome Trust, London, U.K., https://www.fil.ion.ucl.ac.uk/spm/). T1� images
were segmented into gray matter, white matter and cerebrospinal fluid, normalized to the
Montreal Neurological Institute (MNI) space and smoothed using an 8 mm full-width at half
maximum (FWHM) Gaussian kernel. To compute GMV, defined as relative proportion of
grey matter in a region, accounting for brain size and shape, we applied voxel-based mor-
phometry in SPM12 to the preprocessed T1� images applying an absolute threshold of 0.2 to
the modulated grey matter segmentations. We calculated the total intracranial volume by add-
ing the segmented grey matter, white matter and cerebrospinal fluid volumes. We carried out
preprocessing for CoTh analyses using the standard FreeSurfer pipeline for cortical recon-
struction 5.3.0 (Laboratory for Computational Neuroimaging at the Athinoula A. Martinos
Center for Biomedical Imaging, Boston, U.S.A., http://surfer.nmr.mgh.harvard.edu/). This
includedautomatic motion correction, segmentation, intensity normalization, inflation and
registration to a spherical atlas.
We quantified resting-state cerebral blood flow (rsCBF, ml/100g/min) according to a previ-
ously applied, standardized protocol [39–41] using the following formula:
CBF ¼
l � DM




e  w=T1b   e  ðtþwÞ=T1bÞ
� �
;
where ΔM is the difference between labeled and control image; λ the blood/tissue water parti-
tion coefficient (assumed 0.9); α the tagging efficiency (assumed 0.85); M0 the equilibrium
brain tissue magnetization; τ the tagging duration; w the post-labeling delay; and T1b the longi-
tudinal relaxation time of blood (1650ms) [40]. This resulted in 40 unprocessed rsCBF maps
per subject. They were realigned and co-registered to the corresponding raw T1� image and
normalized using the deformation matrix of the corresponding T1� image. We smoothed the
resulting images with a 8mm FWHM Gaussian kernel. We then calculated grey matter rsCBF
applying grey matter masks based on the segmented grey matter T1� images which were thre-
sholded at 0.3. We conducted subject-wise first-level generalized linear models with rsCBF of
the grey matter as outcome variable and the rsCBF of the white matter, the rsCBF of the cere-
brospinal fluid and the realignment parameters as explanatory variables to correct for residual
motion and artifacts. We checked six motion parameters (x-, y-, z-translations, roll, pitch, and
yaw) and set a limit of two voxels of motion for exclusion. This resulted in 40 preprocessed
grey matter rsCBF maps per subject. There was no significant difference between groups in
motion and we did not exclude any subject due to excessive motion. To increase the signal-to-
noise ratio, we finally modelled a mean rsCBF map for each subject based on the 40 prepro-
cessed maps. We used this mean rsCBF map for further analysis and computed mean global
rsCBF within grey matter per subject based on this mean rsCBF map. Preprocessing of rsCBF
maps was performed in SPM12 and Matlab (MATLAB 2015a; The MathWorks, Inc., Natick,
MA, USA).
BOLD images were co-registered to the corresponding raw T1� image and then processed
using the standard processing pipeline in CONN (Version 15, http://www.nitrc.org/projects/
conn). This included realignment; slice-time correction; outlier-detection using ART-
toolbox (global-signal z threshold 9, subject motion threshold 2 mm); normalization;
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smoothing with a 8 mm FWHM kernel; denoising by linear regression of white matter and
cerebrospinal fluid signals, realigning and scrubbing parameters; and finally linear detrending
as well as band-pass filtering between 0.008 and 0.09 Hz. Again, there was no significant differ-
ence between groups in motion and we did not exclude any subject due to excessive motion.
We entered the 11 ROIs that were constructed based on Dehghan et al. [8] as described above
and calculated rsFC between each pair of ROI for each subject by averaging and correlating
the time-series of each ROI.
Statistical analysis
To explore differences in rsCBF, GMV and CoTh between patients and controls we performed
generalized linear models based on whole-brain voxel-wise (vertex-wise for CoTh) analyses
and ROI-analyses. The whole-brain analyses of rsCBF was the main statistical analysis. We
considered disease status (fibromyalgia patients vs pain-free controls) as primary explanatory
variable. When modelling the unadjusted group difference of rsCBF we included mean global
rsCBF as co-variable. Similarly, we included total intracranial volume as co-variable when
modelling unadjusted group differences of GMV and CoTh. To account for the effects of
depression and anxiety we also modelled adjusted group differences of all neuroimaging mark-
ers and additionally included BDI-II and STAI-Trait t-value as co-variables. We followed this
approach for both, whole-brain and ROI analyses of rsCBF, GMV and CoTh. We explored
group differences in rsFC and calculated adjusted group differences of rsFC for each pair of
the 11 pre-specified ROIs and compared rsFC between patients and controls for all resulting
55 connections. Again, we included BDI-ll and STAI-Trait t-values as co-variables to account
for the effects of depression and anxiety. Age was corrected for in the study design using fre-
quency matching of cases and controls according to age. To correct for multiple comparisons,
we used family wise error (FWE) in all analyses withcorrection at peak-level in whole-brain
analyses.
We ran two sets of exploratory sensitivity analyses. First, we performed adjusted subgroup
whole-brain analyses of the difference in rsCBF, GMV and CoTh between patients not taking
any centrally acting drugs and their matched controls. Second, we explored the correlation of
neuroimaging markers with clinical pain characteristics using Pearson correlation. We consid-
ered all neuroimaging markers with group differences at p�0.10 in any of the analyses after
correction for multiple comparisons. Due to the exploratory nature of these correlation analy-
ses, multiple comparison correction was not employed. All reported p-values are two-sided
and all confidence intervals refer to 95% boundaries. We performed statistical analyses for
rsCBF and GMV in SPSS 23.0 (Version 23.0. Armonk, NY: IBM Corp., ROI-analyses, correla-
tions)for CoTh in FreeSurfer (Version 5.3.0., http://surfer.nmr.mgh.harvard.edu/) and for
rsFC in CONN (Version 15, http://www.nitrc.org/projects/conn).
Results
Study flow
We randomly selected and screened 151 fibromyalgia patients and 418 controls. The three
most important reasons for excluding patients were neurologic or psychiatric co-morbidity
other than unipolar depressive disorder (33 patients, 22%), inability to confirm fibromyalgia
diagnosis at enrollment (23 patients, 15%) and inability to perform MRI (9 patients, 6%). The
three most important reasons for excluding controls were neurologic or psychiatric co-mor-
bidity (86 controls, 21%), chronic pain at enrollment (73 controls, 17%) and severe somatic
co-morbidity (44 controls, 10%). We included 32 fibromyalgia patients and 32 age-matched
PLOS ONE Neuroimaging central pain processing fibromyalgia
PLOS ONE | https://doi.org/10.1371/journal.pone.0235879 February 2, 2021 6 / 18
pain-free controls. All participants were female and right-handed. S1 Fig presents the study
flow diagram.
Socio-demographic, psychological and clinical characteristics
Table 1 presents the socio-demographic and psychological characteristics of the study popula-
tion. Cases and controls were comparable in terms of age, education, and marital status.
Patients had significantly higher scores for depression (p� 0.001) and anxiety (p� 0.001).
Twenty-four patients (75%) had widespread body pain affecting more than 50% of their body
and 20 patients (63%) reported average pain intensity of at least NRS 6. All patients took pain
medications on a daily basis; 21 (66%) of them regularly took centrally acting drugs such as
weak opioids, antidepressants or anticonvulsants (intake of strong opioids was an exclusion
criterion).
Differences in resting-state cerebral blood flow and correlation with pain
characteristics
We found no increase in rsCBF in fibromyalgia patients as compared to pain-free controls in
whole-brain analyses with and without depression and anxiety as additional co-variables. We
found significant lower rsCBF in patients in the right Dorsolateral Prefrontal Cortex (x = 44;
y = 32; z = 26; cluster size = 13 voxels; T = -4.39; pFWE = 0.03) in unadjusted analyses (Fig 1A)
and in the left Inferior Middle Temporal Gyrus (x = -50; y = -50; z = -4; cluster size = 110
voxels; T = -6.01, pFWE = 0.002) in adjusted analyses (Fig 2A). However, rsCBF in these two
regions was not correlated with average pain intensity 24h before or pain intensity immedi-
ately before neuroimaging, spread of pain or disability in 32 fibromyalgia patients (Figs 1
and 2B).
Table 1. Baseline characteristics of fibromyalgia patients and pain-free controls.
Fibromyalgia patients (N = 32) Pain-free controls (N = 32) p-value
Socio-demographic characteristics
Age (years) 50.7 (10.0) 52.5 (11.2) 0.49+
Higher education 12 (38%) 8 (25%) 0.28˚
Married 20 (63%) 19 (59%) 0.80˚
Psychological characteristics
Depression (BDI-ll) 20.7 (10.5) 2.9 (4.3) <0.001+
Anxiety (STAI Trait t-value) 61.2 (9.1) 46.8 (7.1) <0.001+
Pain characteristics
Average pain intensity during 24 hours prior to scanning (NRS) 6.2 (1.9) n.a. n.a.
Pain intensity immediately before scanning (NRS) 6.0 (2.2) n.a. n.a.
Degree of spread of pain (WPI) 12 (4) n.a. n.a.
Disability (FIQ) 61 (17) n.a. n.a.
Values are numbers (percentage) or mean (standard deviation).
BDI-ll: Beck Depression Inventory Version 2
STAI: State Trait Anxiety Index
NRS: Numerical Rating Scale from 0 (no pain) to 10 (maximum pain)
WPI: Widespread pain index from 0 (no body region with pain) to 19 (all body regions with pain)
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Fig 1. Unadjusted difference in resting-state cerebral blood flow (rsCBF) between cases (N = 32) and controls (N = 32) in the right
Dorsolateral Prefrontal Cortex (x = 44; y = 32; z = 26) controlling for mean global rsCBF at cluster-level of 10 voxels (A) and correlation of
pain characteristics with rsCBF of this region within patients (N = 32) (B). Displayed are cluster-sizes of>10 voxels with colors indicating t-
values. NRS: Numerical Rating Scale from 0 (no pain) to 10 (maximum pain). WPI: Widespread pain index from 0 (no body region with pain) to 19
(all body regions with pain). FIQ: Fibromyalgia Impact Questionnaire from 0 (no disability) to 100 (most severe disability). r: correlation
coefficients.
https://doi.org/10.1371/journal.pone.0235879.g001
Fig 2. Adjusted difference in resting-state cerebral blood flow (rsCBF) between cases (N = 32) and controls (N = 32) in the left Inferior Middle
Temporal Gyrus (x = -50; y = -50; z = -4) controlling for mean global rsCBF, depression and anxiety at cluster-level of 10 voxels (A) and
correlation of pain characteristics with rsCBF of this region within patients (N = 32) (B). Displayed are cluster-sizes of>10 voxels with colors
indicating t-values. NRS: Numerical Rating Scale from 0 (no pain) to 10 (maximum pain). WPI: Widespread pain index from 0 (no body region
with pain) to 19 (all body regions with pain). FIQ: Fibromyalgia Impact Questionnaire from 0 (no disability) to 100 (most severe disability). r:
correlation coefficients.
https://doi.org/10.1371/journal.pone.0235879.g002
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Differences in local resting state cerebral blood flow of 11 pre-specified ROIs
Table 2 shows adjusted group differences in local rsCBF of 11 pre-specified ROIs after control-
ling for mean global rsCBF, depression and anxiety. Although in more than half of the areas (7
of 11 ROIs) model-based adjusted mean difference between patients and controls suggest an
increased blood flow in patients, none of the increases was statistically significant without nor
with FWE correction. S1 Table shows unadjusted differences of rsCBF of ROI-analyses only
including mean global rsCBF as co-variable. Again, we were unable to detect relevant group
differences.
Differences in resting-state functional connectivity, grey matter volume
and cortical thickness
We found no differences in rsFC among areas associated with chronic pain in fibromyalgia in
unadjusted or adjusted analyses after FWE correction. There was no evidence for differences
in structural neuroimaging markers (GMV, CoTh) in patients as compared to controls in
whole-brain analyses before or after FWE-correction. Tables 3 and 4 report group differences
adjusted for total intracranial volume, depression and anxiety in GMV and CoTh of ROI-anal-
yses. Patients showed non-significant decreases in structural neuroimaging markers in 8 of 10
ROIs for GMV and 12 of 23 ROIs for CoTh with and without FWE correction. S2 and S3
Tables showunadjusted differences of ROI-analyses of GMV and CoTh including only total
intracranial volume as co-variable. As in adjusted analyses, we were unable to detect relevant
group differences.




Brain area� Mean rsCBF (SD) fibromyalgia
patients
Mean rsCBF (SD) pain-free
controls




-48 -27 24 L insula 36.65 (11.27) 36.07 (11.12) 1.97 (-5.98, 9.92) 0.50 0.62 1.0
39 4 1 R insula 45.06 (13.63) 43.43 (12.19) 2.06 (-6.82, 10.93) 0.46 0.65 1.0
43 -2 1 R insula 45.74 (13.25) 41.89 (14.70) -1.57 (-11.46, 8.32) -0.32 0.75 1.0
-46 -12 5 L STG/insula 52.60 (17.43) 47.69 (14.60) 1.24 (-10.34, 12.82) 0.21 0.83 1.0
56 -23 5 R STG 52.88 (12.50) 50.46 (12.16) 1.15 (-7.03, 9.33) 0.28 0.78 1.0
-15 -48 72 L SI 25.52 (14.08) 20.48 (45.91) 10.15 (-16.50, 36.79) 0.76 0.45 1.0
-62 -25 17 L SII 43.96 (11.01) 42.49 (12.67) 3.71 (-4.06, 11.47) 0.96 0.34 1.0
-2 48 -12 L ACC 31.07 (19.80) 35.97 (16.49) -6.31 (-18.20, 5.59) -1.06 0.29 1.0
-17 30 31 L MCC 27.87 (10.07) 27.39 (12.76) -1.73 (-10.19, 6.74) -0.41 0.68 1.0
13 -55 7 R lingual
gyrus
52.79 (13.08) 47.92 (10.38) 3.58 (-3.91, 11.07) 0.96 0.34 1.0
27 -12 -15 R amygdala 47.79 (15.15) 45.16 (13.26) -4.14 (-14.63, 6.34) -0.79 0.43 1.0
Results are data-based mean rsCBF with corresponding standard deviation (SD) and model-based adjusted mean differences of rsCBF with corresponding 95%
confidence intervals (95% CI), t-values and p-values from multivariable general linear models.
� ROI selection based on Dehghan, M., et al., Coordinate-based (ALE) meta-analysis of brain activation in patients with fibromyalgia. Hum Brain Mapp, 2016. 37(5):
p. 1749–58. with 27 voxels (216mm3) boxes centered on MNI-coordinates
Positive adjusted mean differences suggest increased regional rsCBF in patients as compared to controls after controlling for mean global rsCBF, depression and anxiety
MNI: Montreal Neurological Institute coordinates
FWE: Family Wise Error correction for multiple comparison L: Left, R: right
STG: superior temporal gyrus, SI: primary sensory cortex, SII: secondary sensory cortex, ACC: anterior cingulate cortex, MCC: middle cingulate cortex
https://doi.org/10.1371/journal.pone.0235879.t002
PLOS ONE Neuroimaging central pain processing fibromyalgia
PLOS ONE | https://doi.org/10.1371/journal.pone.0235879 February 2, 2021 9 / 18
Subgroup analyses of patients not taking centrally acting drugs
Adjusted whole-brain subgroup-analyses, including depression, anxiety, and mean global
rsCBF or total intracranial volume as co-variables, of 11 (34%) patients not taking centrally
acting drugs and matched controls showed no group differences in rsCBF, GMV and CoTh.
Discussion
Main findings
To our knowledge, this is the first multimodal neuroimaging study integrating four different
functional and structural markers of chronic pain in fibromyalgia. Our primary objective was
to compare rsCBF patterns of fibromyalgia patients and pain-free controls using ASL as mea-
sure of neural activity at rest and thus likely to reproduce a neuroimaging marker of chronic,
stimulus-independent pain. Based on the pathophysiological concept of enhanced central pain
processes, we expected an increased neural activity at rest in pain processing areas, i.e., an
increased rsCBF in these brain areas in cases as compared to controls. Contrary to our hypoth-
esis, we found no evidence of increases in rsCBF in brain areas involved in pain processing in
fibromyalgia neither in whole-brain nor in ROI analyses. Instead, we found decreased rsCBF
in patients in the right Dorsolateral Prefrontal Cortex in whole-brain analysis after controlling
for mean global rsCBF and in the left Inferior Middle Temporal Gyrus in whole-brain analyses
adjusted for mean global rsCBF, depression and anxiety, even after correcting for multiple
comparisons. However, rsCBF in these two areas did not correlate with pain characteristics
such as pain intensity, spread of pain or disability in patients.
Table 3. Adjusted differences in grey matter volume between (GMV) 32 fibromyalgia patients and 32 pain-free controls in 10 pre-specified Regions of Interest.
MNI
coordinates
Brain area� Mean GMV (SD) fibromyalgia
patients
Mean GMV (SD) pain-free
controls








-35 5 2 L insula 0.44 (0.05) 0.45 (0.05) -0.01 (-0.04, 0.02) -0.63 0.53 1.0
39 5 1 R insula 0.43 (0.06) 0.44 (0.05) -0.01 (-0.04, 0.03) -0.43 0.67 1.0
-53 -22 6 L STG 0.37 (0.04) 0.38 (0.04) -0.01 (-0.04, 0.02) -0.56 0.58 1.0
58 -23 5 R STG 0.35 (0.05) 0.36 (0.04) -0.01 (-0.04, 0.01) -1.06 0.30 1.0
-43 -24 48 L postcentral gyrus
(SI)
0.29 (0.03) 0.30 (0.04) -0.01 (-0.03, 0.02) -0.58 0.56 1.0
-47 -10 13 L rolandic operculum
(SII)
0.39 (0.05) 0.40 (0.05) -0.01 (-0.04, 0.02) -0.59 0.56 1.0
-4 34 13 L ACC 0.38 (0.05) 0.39 (0.04) 0.00 (-0.03, 0.03) -0.20 0.84 1.0
-6 -16 40 L MCC 0.39 (0.05) 0.40 (0.04) 0.01 (-0.02, 0.03) 0.43 0.67 1.0
16 -68 -5 R lingual gyrus 0.40 (0.04) 0.42 (0.05) -0.02 (-0.04, 0.01) -1.26 0.21 1.0
27 -1 -19 R amygdala 0.51 (0.04) 0.52 (0.04) -0.02 (-0.04, 0.00) -2.04 0.05 0.5
Results are data-based mean GMV with corresponding standard deviation (SD) and model-based adjusted mean differences of GMV with corresponding 95%
confidence intervals (95% CI), t-values and p-values from multivariable general linear models.
� ROI selection based on Tzourio-Mazoyer, N., et al., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI
MRI single-subject brain. Neuroimage, 2002. 15(1): p. 273–89. Provided coordinates are the centers of mass of the ROIs
Negative adjusted mean differences suggest decreased GMV in patients as compared to controls after controlling for total intracranial volume, depression and anxiety
MNI: Montreal Neurological Institute coordinates. Coordinates are centres of mass.
FWE: Family Wise Error correction for multiple comparison
L: left, R: right
STG: superior temporal gyrus, SI: primary sensory cortex, SII: secondary sensory cortex, ACC: anterior cingulate cortex, MCC: middle cingulate cortex
https://doi.org/10.1371/journal.pone.0235879.t003
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We believe that the decrease in rsCBF in the Dorsolateral Prefrontal Cortex is likely to be
an effect of depression as the role of the Dorsolateral Prefrontal Cortex in depression is well
established [42, 43] and the effect could not be observed anymore after controlling the analysis
for depression. With regard to the decreased rsCBF in the Inferior Middle Temporal Gyrus we
propose that this effect may either indicate a process secondary to the pain experience, such as
the subjective evaluation of pain, or a false positive statistical finding rather than an effect
Table 4. Adjusted differences in cortical thickness (CoTh, mm) between 32 fibromyalgia patients and 32 pain-free controls in 23 pre-specified Regions of Interest.
Region Brain area� Mean CoTh (SD) fibromyalgia
patients









L insula L insula long G and S
centralis
3.15 (0.28) 3.28 (0.29) -0.18 (-0.40, 0.04) -1.66 0.10 1.0
L insula short G 3.56 (0.24) 3.60 (0.27) -0.06 (-0.25, 0.14) -0.56 0.58 1.0
L insula anterior
circular S
2.72 (0.24) 2.72 (0.23) 0.12 (-0.06, 0.30) 1.35 0.18 1.0
L insula inferior
circular S
2.69 (0.19) 2.75 (0.19) 0.00 (-0.14, 0.14) -0.06 0.95 1.0
L insula superior
circular S
2.44 (0.17) 2.43 (0.14) 0.09 (-0.03, 0.21) 1.48 0.14 1.0
R insula long G and S
centralis
3.35 (0.35) 3.43 (0.29) 0.01 (-0.23, 0.26) 0.10 0.92 1.0
R insula short G 3.46 (0.20) 3.52 (0.20) -0.05 (-0.21, 0.10) -0.72 0.48 1.0
R insula anterior
circular S
2.69 (0.22) 2.74 (0.26) -0.02 (-0.20, 0.17) -0.18 0.86 1.0
R insula inferior
circular S
2.67 (0.23) 2.63 (0.19) 0.10 (-0.07, 0.26) 1.17 0.25 1.0
R insula superior
circular S
2.46 (0.14) 2.45 (0.13) 0.04 (-0.06, 0.15) 0.81 0.42 1.0
L STG L transversal STG 2.31 (0.21) 2.36 (0.20) -0.04 (-0.20, 0.12) -0.50 0.62 1.0
L lateral STG 2.98 (0.20) 3.02 (0.22) 0.03 (-0.13, 0.19) 0.36 0.72 1.0
L STG planum polare 3.39 (0.31) 3.44 (0.25) 0.08 (-0.12, 0.28) 0.81 0.42 1.0
L STG planum
temporale
2.42 (0.26) 2.52 (0.23) -0.02 (-0.21, 0.17) -0.20 0.84 1.0
R STG R transversal STG 2.35 (0.24) 2.43 (0.21) -0.13 (-0.31, 0.04) -1.53 0.13 1.0
R lateral STG 2.98 (0.22) 3.01 (0.22) -0.02 (-0.19, 0.15) -0.24 0.81 1.0
R STG planum polare 3.28 (0.28) 3.27 (0.25) 0.06 (-0.13, 0.25) 0.66 0.51 1.0
R STG planum
temporale
2.51 (0.29) 2.49 (0.17) -0.01 (-0.19, 0.18) -0.10 0.92 1.0
SI L postcentral G 2.17 (0.16) 2.24 (0.18) -0.05 (-0.18, 0.08) -0.73 0.47 1.0
SII L subcentral G and S 2.60 (0.15) 2.65 (0.19) -0.04 (-0.17, 0.09) -0.63 0.53 1.0
L Cingulate
Cortex
L ACC 2.53 (0.17) 2.57 (0.22) 0.01 (-0.14, 0.15) 0.08 0.94 1.0
L MCC 2.57 (0.18) 2.58 (0.22) 0.11 (-0.04, 0.26) 1.49 0.14 1.0
R lingual G 2.01 (0.13) 2.02 (0.13) -0.05 (-0.15, 0.05) -1.01 0.31 1.0
Results are data-based mean CoTh with corresponding standard deviation (SD) and model-based mean differences of CoTh with corresponding 95% confidence
intervals (CI), t-values and p-values from multivariable general linear models.
� ROI selection based on Destrieux, C., et al., Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage, 2010. 53
(1): p. 1–15.) No coordinates are provided as this is a surface-based analysis.
Negative adjusted mean differences suggest decreased CoTh in patients as compared to controls after controlling for total intracranial volume, depression and anxiety
FWE: Family Wise Error correction for multiple comparison
L: left; R: right, G: gyrus, S: sulcus
STG: superior temporal gyrus, SI: primary somatosensory cortex, SII: secondary somatosensory cortex, ACC: anterior cingulate cortex, MCC: middle cingulate cortex.
https://doi.org/10.1371/journal.pone.0235879.t004
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attributable to pain. The rationale behind this is fourfold. First, there is no prior evidence for a
pathophysiological involvement of the Inferior Middle Temporal Gyrus in fibromyalgia. Sec-
ond, we detected a decreased rsCBF in this area in patients as compared to controls which is
contrary to our main hypothesis of increased rsCBF in cases as result of central hypersensitiv-
ity. Third, we did not find any relevant correlations between rsCBF in this area and pain char-
acteristics. Fourth, we were unable to see any group differences between cases and controls in
this area for other neuroimaging marker. In view of the large number of analyses conducted, a
false positive statistical finding is a possible explanation.”
Our secondary objective was to compare resting-state functional connectivity between pre-
specified areas likely to be involved in pain processing, grey matter volume and cortical thick-
ness between cases and controls assuming a reduction in these neuroimaging markers in fibro-
myalgia. Again contrary to our hypotheses, we neither found evidence of decreased rsFC,
GMV or CoTh in brain areas involved in pain processing of fibromyalgia patients. The results
remained robust in sensitivity analyses comparing fibromyalgia patients not taking centrally
acting drugs with corresponding controls.
Scientific context of our findings
There is ongoing debate to what extent brain areas processing acute pain signals are also
involved in the development and maintenance of chronic, stimulus-independent pain [8, 17].
We therefore defined the whole-brain analysis as the main statistical approach and performed
secondary ROI analyses based on the recent meta-analysis by Dehghan and colleagues as most
comprehensive evidence synthesis of functional and structural alterations in the central ner-
vous system of fibromyalgia patients [8]. Previous neuroimaging studies typically focused on
the comparison of acute pain processing mechanisms between fibromyalgia patients and pain-
free controls using experimentally-evoked pain paradigms [7]. However, neuroimaging of
chronic, stimulus-independent pain requires a different approach. Chronic pain typically
remains constant during the course of an imaging session, rendering it invisible to traditional
imaging techniques using pain paradigms. Task-free, resting-state parameters such as rsCBF
are markers for brain activity at rest and thus more appropriate to measure chronic pain [18–
20]. ASL is the sequence of choice to measure rsCBF [17]. Still, studies using rsCBF based on
ASL are sparse in pain research with only one study up until now performed in fibromyalgia
[24–29]. Although these studies employed a resting-state paradigm, none them integrated
functional and structural neuroimaging by using multimodal scanning methods and none of
them considered the effect of centrally acting drugs typically used by chronic pain patients on
their results. Furthermore, only some of these studies addressed important confounders such
as age, gender and concomitant depression. To our knowledge, Shokouhi and colleagues con-
ducted the only study using ASL in fibromyalgia investigating resting state perfusion patterns
[29]. They compared 23 patients with 16 pain-free controls and thus included a much smaller
and unmatched study population as compared to our study. They reported hypoperfusion in
the putamen in subjects with chronic pain that was correlated with degree in disability but not
pain intensity thus suggesting that this hypoperfusion was due to adaptation processes. The
correlation between rsCBF in the Putamen and disability was positive when using the Pain
Disability Index to measure disability but negative when using the Fibromyalgia Impact Ques-
tionnaire as other measure of disability. The authors didn’t comment on this conflicting find-
ing. However, they didn’t find group differences of rsCBF between fibromyalgia patients and
controls what is in line with our findings. With regards to the literature on functional connec-
tivity in fibromyalgia patients, our objective was to compare rsFC between pre-specified areas
likely to be involved in pain processing as defined by Dehghan and colleagues [8]. Previous
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studies investigated rsFC of the Default Mode Network. These studies found an increased
connectivity within the Default Mode Network and between the Insula and the Default Mode
Network [21, 22]. The most recent meta-analysis investigating GMV showed grey matter
decreases in the anterior and posterior cingulate cortex, the medial prefrontal cortex and the
parahippocampal gyrus or fusiform cortex [44]. However, the original studies which were
included in this meta-analysis [9–13] and the latest study investigating CoTh [14] typically did
not correct for co-morbid depression or for multiple comparisons, and if they did, group dif-
ferences in neuroimaging markers lost statistical significance [9–14]. Therefore, our inability
to find relevant group differences in structural neuroimaging markers are in line with the find-
ings of these previous studies [9–14]. Furthermore, evidence generation in the field of neuro-
imaging and fibromyalgia is still in its early stage. This phase of evidence generation is often
characterized by conflicting findings as expression of the evidence accumulating process itself,
previously referred to as proteus phenomenon [45, 46]. Therefore, our inability to find evi-
dence to support the hypothesis of altered central pain processing might also be interpreted in
the light of this phenomenon.
Strengths and limitations
Major strengths of the present study include integration of four different functional and struc-
tural neuroimaging markers using a multimodal scanning protocol, evaluation of rsCBF using
ASL; adjustment for depression and anxiety; correction for multiple comparisons and perfor-
mance of a sensitivity analysis in a subgroup of patients not taking centrally acting drugs.
Although fibromyalgia is characterized by intensive, widespread pain not sufficiently explained
by peripheral lesions [7, 12] making it a good model to study the pathophysiology of enhanced
central pain mechanisms it also shows high co-morbidity with depression and anxiety. This
may bias neuroimaging of chronic pain since brain areas involved in pain processing overlap
with those involved in the pathophysiology of depression, e.g. prefrontal, cingulate, and sup-
plementary motor cortex [39]. Pain processing is tightly linked to top-down emotional control
processes involving prefrontal cortices and amygdala [47]. Hence, we adjusted all our analyses
for depression and anxiety and again were unable to find any group differences. Another prob-
lem of studies in fibromyalgia is the long-term treatment with centrally acting drugs, which
may also interfere with neuroimaging markers. For possible rebound-effects and ethical rea-
sons we decided not stop current medication. To address this limitation, we performed a sub-
group-analysis including only patients not taking any centrally acting drugs and matched
controls. We again found no group differences in whole-brain analyses of rsCBF, GMV and
CoTh. We recruited both cases and controls in the only tertiary care hospital in the capital of
Switzerland, with the same referral pathways for fibromyalgia patients and pain-free controls.
This allowed us sampling cases and controls from the same source population, which is impor-
tant to avoid selection bias in case-control studies. Severity of fibromyalgia measures by the
FIQ in our patients was similar to patients included in key randomized controlled trials evalu-
ating non-pharmacological interventions [48, 49] and phase III effectiveness trials of different
drugs [50, 51]. Our study included totally 64 participants, making it one of the largest in the
field. Therefore, we do not think that our inability to observe statistically significant group dif-
ferences was merely due to a lack of power. Our results were consistent across four imaging
modalities and robust to the type of analysis (whole-brain and ROI-analyses, subgroup analysis
in patients not taking centrally acting drugs). Additionally, we were unable to detect relevant
correlation between neuroimaging markers with clinically important outcomes such as pain
intensity, spread of pain and disability. Still, an argument for limited power to detect relevant
group differences is the fact that patients showed numerically increased rsCBF, decreased
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GMV and decreased CoTh in most of the pre-specified ROIs even after adjusting for depres-
sion and anxiety what would be in line with our a priori hypotheses. Previous studies showing
group-differences were both smaller and of less methodological rigor as compared to our
study. They typically did not account for co-morbid depression and intake of pain-modulat-
ing, centrally acting drugs even though both features are particularly frequent in fibromyalgia
and likely to influence neuroimaging results. Furthermore, by nature, case-control studies
tend to inflate group-differences because severely sick cases are compared to healthy controls.
This suggests that we would have detected moderate differences if they had been present. How-
ever, we did not acquire any fieldmaps and therefore could not correct our analyses for mag-
netic field inhomogeneity potentially leading to decreased sensitivity in detecting group
differences. Yet, we believe that correcting our analyses for field inhomogeneity would not
have changed the interpretation of our findings. Signal quality would have improved in both
groups, the cases and controls alike and a more sensitive method would only have detected
small group differences. The relevance of these small effect sizes, if at all present, would be
equivocal.
Implications
Our findings do not necessarily imply that altered central pain processing is not involved in
fibromyalgia but may demonstrate that currently available functional and structural neuroim-
aging markers are not able to map stimulus-independent pain. Stimulus-independent, chronic
pain may involve subtle functional and structural alterations which might be missed in
medium-sized case-control studies like the present one and could be detected by larger multi-
modal studies also using resting-state designs. Because we analyzed brain areas involved in the
processing of acute pain signals, our results suggest that these areas are unlikely to be involved
in the development and maintenance of chronic, stimulus-independent pain.
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Writing – review & editing: Florian Wüthrich, Andrea Federspiel, Roland Wiest, Niklaus Egl-
off, Stephan Reichenbach, Aristomenis Exadaktylos, Peter Jüni, Michele Curatolo, Sebas-
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